Literature DB >> 28209494

Effect of early-onset preeclampsia on cardiovascular risk in the fifth decade of life.

Anouk Bokslag1, Pim W Teunissen2, Constantijn Franssen3, Floortje van Kesteren4, Otto Kamp5, Wessel Ganzevoort6, Walter J Paulus7, Christianne J M de Groot8.   

Abstract

BACKGROUND: Women with hypertensive disorders in pregnancy, in particular early-onset preeclampsia, are at increased risk of developing cardiovascular disease later in life. These women have a more than 2-fold increased risk of dying from cardiovascular diseases. Most studies have focused on identification of risk factors shortly after pregnancy. Less is known on the prevalence of risk factors or actual signs of cardiovascular disease 5-20 years later. The presence of hypertension or metabolic syndrome can be seen as an opportunity for preventive interventions to reduce the development of severe cardiovascular diseases like myocardial infarction and stroke.
OBJECTIVE: To assess cardiovascular risk factors and established cardiovascular disease in women after early-onset preeclampsia, in the fifth decade of life. As a consequence, we can assess whether there is still a window of opportunity for preventive measures and to establish in what proportion of women cardiovascular disease already has developed. STUDY
DESIGN: In a prospective observational study, cardiovascular risk assessment was performed in women with early-onset preeclampsia (<34 weeks' gestation) and normotensive controls (≥37 weeks' gestation) 9-16 years after their index pregnancy. Medical records of 2 tertiary hospitals in Amsterdam, The Netherlands, were screened consecutively, and all eligible women were invited. Cardiovascular risk assessment consisted of a questionnaire, blood pressure measurement, anthropometrics, and blood and urine for fasting lipids, lipoproteins, glucose levels, glycated hemoglobin, renal function, N-terminal brain natriuretic peptide, and albuminuria. History of cardiovascular diseases (ie, myocardial infarction and stroke) was determined. Prevalence of women presenting in an optimal window of opportunity for preventive measures was defined by the presence of cardiovascular risk factors (ie, hypertension and metabolic syndrome) but in the absence of established cardiovascular diseases (ie, myocardial infarction and stroke).
RESULTS: Women with a history of early-onset preeclampsia (n = 131) had significantly greater systolic and diastolic blood pressure, greater body mass index, more often had an abnormal lipid profile (lower high-density lipoprotein levels, higher triglycerides), greater glycated hemoglobin, and greater levels of albuminuria compared to controls (n = 56). None of the women with a history of early-onset preeclampsia was diagnosed with cardiovascular disease; 38.2% were diagnosed with hypertension; and 18.2% were diagnosed with metabolic syndrome. A total of 42% met the criteria for the window of opportunity for preventive measures. In women with a history of an uncomplicated pregnancy, no women were diagnosed with cardiovascular disease; 14.3% were diagnosed with hypertension; 1.8% with metabolic syndrome. In this cohort, 14.3% met the criteria for the window of opportunity for preventive measures.
CONCLUSION: A large proportion of women who experienced early-onset preeclampsia had major cardiovascular risk factors in the fifth decade of life, compared with healthy controls. These women are currently outside the scope of most preventive programs due to their relatively young age, but have important modifiable risk factors for cardiovascular diseases.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiovascular disease; cardiovascular risk factors; early-onset preeclampsia; metabolic syndrome; preeclampsia; prevention; women’s health

Mesh:

Substances:

Year:  2017        PMID: 28209494     DOI: 10.1016/j.ajog.2017.02.015

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  28 in total

Review 1.  Hypertensive Disorders of Pregnancy and Future Maternal Health: How Can the Evidence Guide Postpartum Management?

Authors:  Alisse Hauspurg; Malamo E Countouris; Janet M Catov
Journal:  Curr Hypertens Rep       Date:  2019-11-27       Impact factor: 5.369

2.  Advanced maternal age impacts physiologic adaptations to pregnancy in vervet monkeys.

Authors:  Maren Plant; Cecilia Armstrong; Alistaire Ruggiero; Chrissy Sherrill; Beth Uberseder; Rachel Jeffries; Justin Nevarez; Matthew J Jorgensen; Kylie Kavanagh; Matthew A Quinn
Journal:  Geroscience       Date:  2020-06-25       Impact factor: 7.713

Review 3.  Sex differences in stroke co-morbidities.

Authors:  Taylor E Branyan; Farida Sohrabji
Journal:  Exp Neurol       Date:  2020-06-23       Impact factor: 5.330

4.  Prospective Evaluation of Cardiovascular Risk 10 Years After a Hypertensive Disorder of Pregnancy.

Authors:  Lisa D Levine; Bonnie Ky; Julio A Chirinos; Jessica Koshinksi; Zoltan Arany; Valerie Riis; Michal A Elovitz; Nathanael Koelper; Jennifer Lewey
Journal:  J Am Coll Cardiol       Date:  2022-06-21       Impact factor: 27.203

Review 5.  Hypertensive Disorders of Pregnancy and Cardiovascular Disease Risk Across Races and Ethnicities: A Review.

Authors:  Renée J Burger; Hannelore Delagrange; Irene G M van Valkengoed; Christianne J M de Groot; Bert-Jan H van den Born; Sanne J Gordijn; Wessel Ganzevoort
Journal:  Front Cardiovasc Med       Date:  2022-06-28

6.  Latency of preterm hypertensive disorders of pregnancy and subsequent cardiovascular complications.

Authors:  Joshua I Rosenbloom; Dustin Stwalley; Kathryn J Lindley; D Michael Nelson; Margaret A Olsen; Molly J Stout
Journal:  Pregnancy Hypertens       Date:  2020-05-31       Impact factor: 2.899

Review 7.  Management of Obstructive Sleep Apnea in Pregnancy.

Authors:  Jennifer E Dominguez; Linda Street; Judette Louis
Journal:  Obstet Gynecol Clin North Am       Date:  2018-06       Impact factor: 2.844

8.  Soluble guanylate cyclase stimulation in late gestation does not mitigate asymmetric intrauterine growth restriction or cardiovascular risk induced by placental ischemia in the rat.

Authors:  Laura E Coats; Bhavisha A Bakrania; Daniel R Bamrick-Fernandez; Allison M Ariatti; Adam Z Rawls; Norma B Ojeda; Barbara T Alexander
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-03-19       Impact factor: 4.733

Review 9.  The impact of COVID-19 on pregnancy and therapeutic drug development.

Authors:  Allyah Abbas-Hanif; Homira Rezai; Syed Faraz Ahmed; Asif Ahmed
Journal:  Br J Pharmacol       Date:  2021-07-06       Impact factor: 9.473

10.  Incidence of essential hypertension but not echocardiographic abnormalities at four years with a history of preeclampsia with severe features.

Authors:  Arthur Jason Vaught; Anum Minhas; Theresa Boyer; Alexia Debrosse; Garima Sharma; Dhananjay Vaidya; Pamela Ouyang; Sammy Zakaria; Monica Mukherjee
Journal:  Pregnancy Hypertens       Date:  2021-06-12       Impact factor: 2.899

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.